Królikowska Kinga, Kurman Natalia, Błaszczak Katarzyna, Ławicki Sławomir, Gudowska-Sawczuk Monika, Zajkowska Monika
Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Bialystok, 15-269 Bialystok, Poland.
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland.
Int J Mol Sci. 2025 May 21;26(10):4937. doi: 10.3390/ijms26104937.
Cancers represent a significant global health concern, being among the most prevalent malignancies and contributing substantially to morbidity and mortality rates. Notably, colorectal, gastric, pancreatic, and liver cancers are the most frequently diagnosed among these malignancies. The pathogenesis of gastrointestinal (GI) cancers is multifactorial, encompassing a complex interplay of genetic predispositions, environmental exposures, and lifestyle choices. Despite advances in diagnostic approaches and therapeutic strategies, existing treatment modalities, particularly in the advanced stages of these cancers, remain ineffective. Recent research efforts have increasingly focused on the identification and characterization of novel biomarkers that could enhance both the detection and treatment of gastrointestinal cancers. One particularly promising area of investigation involves neuropilins (NRPs). NRPs are involved in essential biological processes such as angiogenesis, cellular migration, and tumor cell-microenvironment interactions, all of which promote tumor progression and contribute to the development of treatment resistance. Overexpression of neuropilins has been linked to poor prognosis in patients, implying that they could be useful in diagnosis and serve as targets for molecular treatment. Recent research also suggests that inhibiting neuropilin activity may slow tumor growth and inhibit angiogenic processes, opening up new possibilities for targeted therapeutic techniques in the treatment of gastrointestinal malignancies.
癌症是全球重大的健康问题,是最常见的恶性肿瘤之一,对发病率和死亡率有重大影响。值得注意的是,结直肠癌、胃癌、胰腺癌和肝癌是这些恶性肿瘤中最常被诊断出的。胃肠道(GI)癌症的发病机制是多因素的,包括遗传易感性、环境暴露和生活方式选择之间的复杂相互作用。尽管诊断方法和治疗策略有所进步,但现有的治疗方式,尤其是在这些癌症的晚期,仍然无效。最近的研究工作越来越集中在新型生物标志物的识别和表征上,这些生物标志物可以提高胃肠道癌症的检测和治疗水平。一个特别有前景的研究领域涉及神经纤毛蛋白(NRP)。NRP参与血管生成、细胞迁移和肿瘤细胞与微环境相互作用等重要生物学过程,所有这些都促进肿瘤进展并导致治疗抗性的产生。神经纤毛蛋白的过表达与患者预后不良有关,这意味着它们可用于诊断并作为分子治疗的靶点。最近的研究还表明,抑制神经纤毛蛋白的活性可能会减缓肿瘤生长并抑制血管生成过程,为胃肠道恶性肿瘤的靶向治疗技术开辟了新的可能性。